more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$37.94 USD

-1.48 (-3.75%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $37.95 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

Bottom 35% (164 out of 251)

Industry: Medical Services

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Patterson Companies (PDCO) Inks Deal to Expand Product Suite

by Zacks Equity Research Published on November 11,2022

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.

BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up

by Zacks Equity Research Published on November 10,2022

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.

QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research Published on November 10,2022

The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research Published on November 10,2022

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

medical-devices

STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research Published on November 10,2022

Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.

earnings

Should Value Investors Buy AMN Healthcare Services (AMN) Stock?

by Zacks Equity Research Published on November 10,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research Published on November 10,2022

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.